论文部分内容阅读
目的探讨氟马西尼诊疗药物中毒所致昏迷患者的临床价值。方法选取2013年4月至2015年9月辽宁省本溪市康宁医院收治的68例药物中毒所致昏迷患者作为研究对象,根据治疗方法不同将其分为对照组和观察组,各34例。观察组患者采用氟马西尼进行治疗,对照组患者给予纳洛酮,比较两组患者的临床疗效。结果治疗后,观察组患者的镇静程度评分显著低于对照组,差异有统计学意义(P<0.05);观察组患者的语言反应、睁眼反应、运动反应评分均明显高于对照组,差异均有统计学意义(均P<0.05);观察组浅昏迷、深昏迷患者苏醒时间均明显短于对照组,差异均有统计学意义(均P<0.05);观察组患者的病死率明显低于对照组,治愈率明显高于对照组,差异均有统计学意义(均P<0.05);观察组患者的不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。结论氟马西尼治疗药物中毒所致昏迷患者临床疗效显著,能够有效缩短患者的昏迷时间,改善镇静程度,提高治愈率,降低不良反应发生率。
Objective To investigate the clinical value of flumazenil in the treatment of coma caused by drug poisoning. Methods From April 2013 to September 2015, 68 patients with coma caused by drug poisoning admitted to Corning Hospital of Benxi City in Liaoning Province were selected as research objects. According to the different treatment methods, they were divided into control group and observation group, with 34 cases in each group. Patients in the observation group were treated with flumazenil, while those in the control group were given naloxone. The clinical efficacy of the two groups was compared. Results After treatment, the scores of sedation in the observation group were significantly lower than those in the control group (P <0.05). The language response, eyes open reaction and motor response score in the observation group were significantly higher than those in the control group (All P <0.05). The awake time of observation group was significantly shorter than that of control group (all P <0.05), and the mortality of observation group was significantly lower than that of control group In the control group, the cure rate was significantly higher than the control group, the difference was statistically significant (all P <0.05); adverse reactions in the observation group was significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion Flumazenil treatment of drug-induced coma in patients with significant clinical efficacy, can effectively shorten the coma of patients, to improve the sedation, improve the cure rate and reduce the incidence of adverse reactions.